Trial Information

Summary: A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon beta 1-a and Glatiramer Acetate to Either Agent Alone in Patients with Relapsing-Remitting Multiple Sclerosis (CombiRx Phase III)

A multi-center, National Institutes of Health-National Institute of Neurological Disorders and Stroke (NIH-NINDS) supported clinical trial examining the combined use of Interferon beta 1-a weekly and Glatiramer Acetate daily as initial treatment for patients with relapsing remitting multiple sclerosis. The purpose of the study is to determine if the combined use of these agents will help reduce relapse rate when compared to either agent alone. The study is being conducted at approximately 85 sites across the US and Canada. Eligible patients will be required to visit their local clinic every three months over a three year period (15 scheduled visits). All study-related visits and investigational drug therapies are provided at no cost. To find a participating study center or site in your area or for more information, please call 1-866-848-3088.
No Compensation Provided

Patient Inclusion/Exclusion Criteria:

Men and women between 18 and 60 years of age whom:
- Have been diagnosed with relapsing-remitting MS
- Are not pregnant, breast-feeding or planning to become pregnant
- Are willing and able to give informed consent to participate

- Previous treatement with Interferon beta 1-a (Avonex) or Glatiramer Acetate (Copaxone)
- Participation in another experimental clinical trial
- History of any signficant heart, liver, lung or kidney disease or immune deficiency

If you would like to learn more about participating in this study, please send an e-mail message using the form below.